Mp53-20 Radium-223(rad) in Men With Symptomatic Castration-Resistant Prostate Cancer: Guideline Versus Clinical Reality.

Radium-223 for metastatic castration-resistant prostate cancer: results and remaining open issues after the ALSYMPCA trial

“…The most common treatment related adverse event (TRAE) reported in the initial phase III approval study included grade 3 or 4 myelosuppression (radium-223 vs. placebo: anemia, 13% vs. 13%; neutropenia, 2% vs. 1%; and thrombocytopenia, 7% vs. 2%) ( 3 ). Also a real-life study conducted by our working group presented at the AUA 2017 conference revealed similar TRAEs as well as response and OS rates in the daily routine ( 5 ). Interestingly, a recently published sub-analysis von ALSYMPCA showed that significantly fewer radium-223 versus placebo patients had at least one hospitalization event and also hospitalization days per patient for radium-223 ( 6 ).…”